Dr. Ari D Baron, M.D. | Sutter Health

Dr. Ari Baron, MD

Claim this profile

Alta Bates Summit Medical Center-Herrick Campus

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
30 reported clinical trials
68 drugs studied

Area of expertise

1Lung Cancer
Ari Baron, MD has run 10 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
RET positive
2Non-Small Cell Lung Cancer
Ari Baron, MD has run 9 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
MET positive
RET positive

Affiliated Hospitals

Image of trial facility.
Alta Bates Summit Medical Center-Herrick Campus
Image of trial facility.
California Pacific Medical Center-Pacific Campus

Clinical Trials Ari Baron, MD is currently running

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Image of trial facility.

Olaparib

for Pancreatic Cancer

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria

More about Ari Baron, MD

Clinical Trial Related8 years of experience running clinical trials · Led 30 trials as a Principal Investigator · 10 Active Clinical Trials
Treatments Ari Baron, MD has experience with
  • Pembrolizumab
  • Nivolumab
  • Irinotecan Hydrochloride
  • Fluorouracil
  • Leucovorin Calcium
  • Gemcitabine Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Ari Baron, MD specialize in?
Is Ari Baron, MD currently recruiting for clinical trials?
Are there any treatments that Ari Baron, MD has studied deeply?
What is the best way to schedule an appointment with Ari Baron, MD?
What is the office address of Ari Baron, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security